Post-Hoc Live

Endpoints News

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations. Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com

  1. 6月22日

    Are the China hawks winning?

    WuXi is back on the Pentagon’s blacklist. The United States Treasury might restrict investments in Chinese biotech. Despite wave after wave of big pharma announcements around partnerships with China, the protectionist voices are taking up more airtime. Where are the winds blowing, and what material impact could this all have? Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

    42分

  2. 6月9日

    How much is everyone in biopharma getting paid?

    CEO pay keeps going up, and up, and up. What do the pay ratios at pharmas say about the state of the industry as a whole, and how do the eye-popping numbers affect global competition? On Post-Hoc Live, we’ll take you behind the scenes of Endpoints’ annual biopharma compensation report, which breaks down pay for top execs and median workers.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

    33分

  3. 5月27日

    How to stabilize US biotech — with Dr. Jeremy Levin

    Jeremy Levin has seen the biopharma industry from practically every vantage point. Now, with decades of experience under his belt, he’s out front in the chorus of veterans sounding the alarm about threats to US dominance in biotech. He joins Post-Hoc Live to talk about China, US policy, and how to stem the bleeding.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

    33分

  4. 5月15日

    Makary's out: Live from the FT Summit

    Marty Makary resigned as FDA commissioner on Tuesday after a turbulent tenure at the head of the agency. The Endpoints and Financial Times teams sat down at the US Pharma and Biotech Summit on Thursday to talk about his tenure, his downfall, and where the FDA goes from here.Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

    29分

  5. 5月12日

    Q1 earnings recap with Endpoints News

    Thanks to our premium subscribers who joined us live for this special episode of Post-Hoc Live. Catch up on the recording now:Are more deals coming, after a deal-heavy Q1? How are IRA negotiations and MFN deals affecting outlooks? What's the state of the oral weight loss race between Novo and Lilly? We’ll dig into key results and predict what they could mean for the rest of the year.

    38分

  6. 4月24日

    Trust, MAHA, and what’s next for the CDC

    The CDC hasn’t had a Senate-confirmed director since August. But last week, President Trump announced his next pick — Erica Schwartz, a former deputy surgeon general. She’s a more traditional public-health choice, and if confirmed, faces the formidable tasks of stabilizing the agency and working with RFK Jr., whose anti-vax and MAHA allies have already criticized the pick. We’re joined by Brinda Adhikari, the host of podcast Why Should I Trust You?, to talk about where the CDC and MAHA go from here.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

    34分

  7. 4月10日

    The spring deals bonanza

    Pharma companies went on a dealmaking spree over the past few weeks, signing acquisitions worth up to $25.5B in two weeks in March alone. It’s shaping up to be a big year — if the pace continues. We’re joined by Emily Field, head of US biopharmaceuticals equity research at Barclays, to break down the factors contributing to the deal flow and make predictions for the rest of the year.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

    37分

  8. 3月31日

    The politics of vaccines — with former congressman Dr. Michael Burgess

    With the midterms looming, Trump’s HHS seems to be backing off vaccines and pivoting toward healthy eating — playing up the aspects of RFK Jr.’s agenda that are popular, rather than those that cater to his base. Is the new focus working, and will it last? We’re joined by former US Representative Dr. Michael Burgess to talk through the political landscape around vaccines and why he thinks it’s a liability for Republicans.

    35分
すべて見る（43）

予告編

番組について

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations. Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com

情報

  • クリエイター
    Endpoints News
  • 配信期間
    25年 - 26年
  • エピソード
    43
  • 制限指定
    不適切な内容を含まない
  • Copyright
    © Endpoints News
  • 番組のWebサイト
    Post-Hoc Live

その他のおすすめ